Different Doses of IVIG for Kawasaki Disease

Learn more about:
Related Clinical Trial
Clinical Precise Diagnosis and Treatment in the Kawasaki Disease A Blood Test to Diagnose Kawasaki Disease Defibrotide in Children With High Risk Kawasaki Disease Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease A Randomized Phase III Multicenter Trial Comparing the Efficacy and Safety of Anakinra Versus Intravenous Immunoglobulin (IVIG) Retreatment, in Patients With Kawasaki Disease Who Failed to Respond to Initial Standard IVIG Treatment Characterization of Multisystem Inflammatory Syndrome in Children (MIS-C) and Its Relationship to Kawasaki Disease Efficacy of Immunoglobulin Plus Infliximab for the Early Regression of Coronary Artery Lesion in Kawasaki Disease Methylprednisolone Pulse Therapy for Coronary Artery Dilatation or Aneurysm Formation in Kawasaki Disease Statins Study in Kawasaki Disease Children With Coronary Artery Abnormalities Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study) Prevention of Coronary Aneurysms in Kawasaki Syndrome A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects Real Time Myocardial Contrast Echocardiography and Dobutamine Stress Perfusion Magnetic Resonance Imaging Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease Anakinra and Kawasaki Disease Study of Combined Therapy of Aspirin and “IVIG-SN” in Kawasaki Disease Study of Combined Therapy IVIG-SN 10% and Acetylsalicylic Acid in Kawasaki Disease Cardiovascular Status of Children 5 Years After Kawasaki Disease Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD. A Multi-center, Randomized to Compare the Efficacy of IVIG Alone and IVIG Plus High-dose Aspirin in Kawasaki Disease Etanercept in Kawasaki Disease Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease Cardiovascular Risk Markers and Response to Statins After Kawasaki Disease Anakinra in Infants and Children With Coronary Artery Abnormalities in Acute Kawasaki Disease Infliximab (Remicade) for Patients With Acute Kawasaki Disease Acute Abdomen in Kawasaki Disease Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease Epidemiologic Features of Kawasaki Disease in Shanghai From 2013 Through 2017 Different Doses of IVIG for Kawasaki Disease Pharmacokinetics (PK)/Safety Study of Atorvastatin in Children With Kawasaki Disease and Coronary Artery Abnormalities Epidemiologic Features of Kawasaki Disease in Shanghai From 2008 Through 2012 Measurement of Antibodies in Adults With a History of Kawasaki Disease Prevalence and Early Markers of Atherosclerosis in Adults With a History of Kawasaki Disease A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease Genetic Determinants of Kawasaki Disease Infliximab for Kawasaki Disease Patients Resistant to IVIG : a Multicentre, Prospective, Randomised Trial KIDCARE (Kawasaki Disease Comparative Effectiveness Trial) Multi-center Prospective Randomized Control Trail of High Dose Aspirin in Acute Stage of Kawasaki Disease

Brief Title

Different Doses of IVIG for Kawasaki Disease

Official Title

Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial

Brief Summary

      The objective of this study is to investigate the effect of different doses of intravenous
      immunoglobulin (IVIG) (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease (KD) in a
      multicentre, prospective,randomised trial.
    

Detailed Description

      Kawasaki disease is an acute febrile illness recognized most often in young children.
      Coronary abnormality is the most serious complication preventable with intravenous
      immunoglobulin (IVIG) administration. Various treatment regimens of IVIG have been
      reported.The optimal administrative doses of IVIG deserves more observations.We will conduct
      a multicenter, randomized, prospective trial to determine the effect of different doses of
      IVIG (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease. The KD children will be
      randomly assigned to three groups and were given different IVIG regimen (1g/kg once, 1g/kg
      twice, 2g/kg once)as initial treatment. Patient age, gender, white blood cell count,
      hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell
      specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be
      analyzed among the three groups. The primary outcome is the duration of fever subsided and
      the incidence of coronary artery lesions .
    

Study Phase

Phase 3

Study Type

Interventional


Primary Outcome

Duration of fever subsided to normal after initial IVIG finished

Secondary Outcome

 incidence of coronary artery lesions(CAL) after IVIG finished

Condition

Kawasaki Disease

Intervention

IVIG (1g/kg,once)

Study Arms / Comparison Groups

 IVIG(1g/kg,once)
Description:  The KD children will be randomly assigned to three groups. The patients in group C will receive IVIG 1g/kg once.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

404

Start Date

January 2014

Completion Date

September 2016

Primary Completion Date

March 2016

Eligibility Criteria

        Inclusion Criteria:

          -  Individual patient's medical file data confirmed the diagnosis of KD using the 5th
             revised edition of diagnostic criteria for KD, issued by the Japan Kawasaki Disease
             Research Committee at the 7th International Kawasaki Disease Symposium in 2002.

          -  the patients aged from 1 months to 12 years old.

          -  All included patients required to sign an informed consent form.

          -  the patients didn't receive treatment before.

        Exclusion Criteria:

          -  The patients with the application of hormone or other immunosuppressive agents;

          -  The patients didn't want to signed informed consent.
      

Gender

All

Ages

1 Month - 12 Years

Accepts Healthy Volunteers

No

Contacts

Guoying Huang, PHD, , 

Location Countries

China

Location Countries

China

Administrative Informations


NCT ID

NCT02439996

Organization ID

KD(2015-2016)


Responsible Party

Principal Investigator

Study Sponsor

Children's Hospital of Fudan University

Collaborators

 Shanghai Children's Medical Center

Study Sponsor

Guoying Huang, PHD, Study Chair, Children Hospital of Fudan University


Verification Date

May 2018